Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater.

The detection of drugs in drinking water sources has raised questions related to safety. In the absence of regulatory or other official guidance, water utilities are faced with a problem of which drugs should be monitored and the detection limits that should be required. The US FDA summarizes data required for drug approval and post marketing adverse reaction reporting. The use of these data as a means of arriving at concentrations in water where adverse health effects are minimal or non-existent was explored. The minimum therapeutic dose was assumed an appropriate point of departure. Appropriate uncertainty factors could be applied depending upon the qualitative and quantitative nature of the data that are available. Assumptions inherent in US FDA's approval of drugs for use in subsets of the population relative to the broader concerns that arise for exposures of the entire population had to be considered. Additional questions are; whether the drug under consideration is carcinogenic, carries pregnancy and lactation warnings, approval for limited vs. chronic use, exposures to multiple compounds that could act in additive or synergistic ways, and the seriousness of toxicities that are observed. Aside from these considerations, a combined uncertainty factor of 1000 appeared adequate.

[1]  B. Spiegelhalder,et al.  Caffeine-derived N-nitroso compounds. II. Synthesis and characterization of nitrosation products from caffeidine and caffeidine acid. , 1993, Chemical research in toxicology.

[2]  Mutsuko Hirata-Koizumi,et al.  Potential adverse effects of phthalic acid esters on human health: a review of recent studies on reproduction. , 2008, Regulatory toxicology and pharmacology : RTP.

[3]  M. Muenke,et al.  Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins , 2004, American journal of medical genetics. Part A.

[4]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002, Environmental science & technology.

[5]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002 .

[6]  Melvin E Andersen,et al.  Perfluoroalkyl acids and related chemistries--toxicokinetics and modes of action. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Simon Webb,et al.  Indirect human exposure to pharmaceuticals via drinking water. , 2003, Toxicology letters.

[8]  W. Woessner,et al.  Pharmaceuticals in On‐Site Sewage Effluent and Ground Water, Western Montana , 2007, Ground water.

[9]  D. Schmähl,et al.  Carcinogenic action of low‐dose cyclophosphamide given orally to sprague‐dawley rats in a lifetime experiment , 1979, International journal of cancer.

[10]  E. Frei,et al.  Caffeine-derived N-nitroso compounds. IV: Kinetics of mononitrosocaffeidine demethylation by rat liver microsomes. , 1994, Cancer letters.

[11]  R. Cox,et al.  Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. , 1994, Teratology.

[12]  J. Henck,et al.  Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  K. Leftheris,et al.  N-Amination of pyrrole and indole heterocycles with monochloramine (NH2Cl). , 2004, The Journal of organic chemistry.

[14]  Valeri Craigle MedWatch–The FDA Safety Information and Adverse Event-Reporting Program , 2007, Red Book (2012).

[15]  T. Ternes,et al.  Pharmaceuticals and personal care products in the environment: agents of subtle change? , 1999, Environmental health perspectives.

[16]  G. Eibl The Role of PPAR-γ and Its Interaction with COX-2 in Pancreatic Cancer , 2008, PPAR research.

[17]  F. Christensen Pharmaceuticals in the environment--a human risk? , 1998, Regulatory toxicology and pharmacology : RTP.

[18]  Edward V. Sargent,et al.  A Human Health Risk Assessment of Pharmaceuticals in the Aquatic Environment , 2002 .

[19]  Kurtis Sarafin,et al.  Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. , 2006, The Science of the total environment.

[20]  J. Uetrecht,et al.  Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. , 1993, Biochemical pharmacology.

[21]  J. Uetrecht,et al.  Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. , 1997, Chemical research in toxicology.

[22]  J. Lazorchak,et al.  Risks to aquatic organisms posed by human pharmaceutical use. , 2008, The Science of the total environment.

[23]  D. Sedlak,et al.  Transformation of aromatic ether- and amine-containing pharmaceuticals during chlorine disinfection. , 2004, Environmental science & technology.

[24]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[25]  D. Sedlak,et al.  Factors controlling nitrosamine formation during wastewater chlorination , 2002 .

[26]  L. A. Dostal,et al.  Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. , 1994, Teratology.

[27]  黄亚明,et al.  RxList , 2012 .

[28]  R. McClelland,et al.  Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. , 1995, Chemical Research in Toxicology.

[29]  D. Pessayre Role of reactive metabolites in drug-induced hepatitis. , 1995, Journal of hepatology.

[30]  P. Stacpoole,et al.  Regulation of rat liver hydroxymethylglutaryl coenzyme A reductase by a new class of noncompetitive inhibitors. Effects of dichloroacetate and related carboxylic acids on enzyme activity. , 1983, The Journal of clinical investigation.

[31]  K Kümmerer,et al.  Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources--a review. , 2001, Chemosphere.

[32]  Thomas Steger-Hartmann,et al.  Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by twostep solid-phase extraction and gas chromatography-mass spectrometry , 1996 .

[33]  E. J. Read,et al.  Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat. , 1992, Teratology.

[34]  Peter Shanahan,et al.  Screening analysis of human pharmaceutical compounds in U.S. surface waters. , 2004, Environmental science & technology.

[35]  R. Robertson,et al.  Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats. , 1995, Teratology.

[36]  T. Borg,et al.  The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns. , 1997, Developmental biology.

[37]  J. Reijneveld,et al.  Differential Effects of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors on the Development of Myopathy in Young Rats , 1996, Pediatric Research.

[38]  P. Anderson,et al.  Human pharmaceuticals in US surface waters: a human health risk assessment. , 2005, Regulatory toxicology and pharmacology : RTP.

[39]  Benjamin D. Stanford,et al.  Evaluation of a photocatalytic reactor membrane pilot system for the removal of pharmaceuticals and endocrine disrupting compounds from water. , 2009, Water research.

[40]  L. Melton,et al.  Melphalan may be a more potent leukemogen than cyclophosphamide. , 1986, Annals of internal medicine.

[41]  Thomas Steger-Hartmann,et al.  Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage , 1997 .

[42]  R. Robertson,et al.  Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. , 1995, Teratology.

[43]  M. Eichelbaum,et al.  Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy , 1979, Clinical pharmacology and therapeutics.

[44]  T. Steger-Hartmann,et al.  Biological degradation of cyclophosphamide and its occurrence in sewage water. , 1997, Ecotoxicology and environmental safety.

[45]  G. Foster,et al.  Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process , 2005, Environmental toxicology and chemistry.

[46]  S. Mirvish Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. , 1995, Cancer letters.

[47]  V. Cunningham,et al.  Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. , 2009, Regulatory toxicology and pharmacology : RTP.

[48]  D. Reckhow,et al.  Use of Chemical Models and Structure-Activity Relationships to Identify Novel Disinfection By Products of Potential Toxicological Concern , 2008 .

[49]  L. M. Libbey,et al.  Isolation and characterization of products from the nitrosation of the alkaloid gramine. , 1985, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[50]  R. Berna,et al.  Toxicokinetic analysis of losartan during gestation and lactation in the rat. , 1996, Teratology.

[51]  N. Kruhlak,et al.  Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. , 2004, Regulatory toxicology and pharmacology : RTP.

[52]  N. Kruhlak,et al.  Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. , 2004, Current drug discovery technologies.

[53]  Ivan Rusyn,et al.  Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver , 2006, Critical reviews in toxicology.

[54]  Ettore Zuccato,et al.  Strategic Survey of Therapeutic Drugs in the Rivers Po and Lambro in Northern Italy , 2003 .

[55]  J. Furr,et al.  A mixture of five phthalate esters inhibits fetal testicular testosterone production in the sprague-dawley rat in a cumulative, dose-additive manner. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[56]  J. T. Sanderson,et al.  The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  F. Gonzalez,et al.  Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. , 2008, Biochemical pharmacology.

[58]  Paul Kay,et al.  Prioritisation of veterinary medicines in the UK environment. , 2003, Toxicology letters.

[59]  Gregory A Loraine,et al.  Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in southern California. , 2006, Environmental science & technology.

[60]  A Bruchet,et al.  A broad spectrum analytical scheme for the screening of endocrine disruptors (EDs), pharmaceuticals and personal care products in wastewaters and natural waters. , 2002, Water science and technology : a journal of the International Association on Water Pollution Research.

[61]  T. Ternes,et al.  The occurrence of micopollutants in the aquatic environment: a new challenge for water management. , 2007, Water science and technology : a journal of the International Association on Water Pollution Research.

[62]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[63]  J. Uetrecht,et al.  Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[64]  D. Mantzavinos,et al.  Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes. , 2009, Environment international.

[65]  J. Uetrecht,et al.  N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications. , 1991, Chemical research in toxicology.

[66]  Joel P Bercu,et al.  Human health risk assessments for three neuropharmaceutical compounds in surface waters. , 2008, Regulatory toxicology and pharmacology : RTP.

[67]  Jaeweon Cho,et al.  Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste waters. , 2007, Water research.

[68]  L Earl Gray,et al.  A mixture of seven antiandrogens induces reproductive malformations in rats. , 2008, International journal of andrology.

[69]  R J Bull,et al.  Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. , 2000, Environmental health perspectives.

[70]  Charles F. Lacy,et al.  Drug Information Handbook , 1998 .

[71]  R. Kroes Structure-Based Thresholds of Toxicological Concern (TTC): Guidance for Application to Substances Present at Low Levels in the Diet , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.